PepKon
Paris
About PepKon
Pepkon is a biotechnology company that develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. PepKon is developing small peptides mimicking the C-terminal domain of Thrombospondin-1. They treat several leukemias and solid cancers, including pediatric and orphan types. PepKon objective is to rapidly reach clinical trials with its lead product PKT16. Based on solid preclinical data, the company is targeting Chronic Lymphocytic Leukemia (CLL) as its first indication. Founded by Philippe Karoyan, Jean Pascal Tranié, and Patric Weil in 2022 and is located in Paris, France.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Last round: Non-Equity Assistance (Mar 2023)
- Website: pepkon.fr
Industries & Categories
Biotechnology, Medical, Product Research
Social Profiles
Canonical: https://fsome.com/organization/pepkon-2686452 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.